The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: Evidence from an updated meta-analysis

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Peng, Qiliu ^a   Lu, Yu ^a   Lao, Xianjun ^a   Chen, Zhiping ^b   Li, Ruolin ^a   Sui, Jingzhe ^a   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

BREAST TUMOR; CASE CONTROL STUDY; CAUCASIAN; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; INCIDENCE; META ANALYSIS; PATHOLOGY; PHENOTYPE; RISK; RISK ASSESSMENT; RISK FACTOR;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; NAD(P)H DEHYDROGENASE (QUINONE); ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84901918873     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-100     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1784-1794. 10.1158/1055-9965.EPI-07-0247, 17726138.
4. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000, 2:903-917. 10.1089/ars.2000.2.4-903, 11213491.
5. Schlager JJ, Powis G. Cytosolic NAD(P)H: (quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990, 45:403-409. 10.1002/ijc.2910450304, 2307529.
6. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004, 65:1238-1247. 10.1124/mol.65.5.1238, 15102952.
7. Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res 2002, 62:1420-1424.
8. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995, 5:199-206. 10.1097/00008571-199508000-00003, 8528266.
9. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997, 75:69-75. 10.1038/bjc.1997.11, 2222704, 9000600.
10. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999, 9:113-121. 10.1097/00008571-199902000-00015, 10208650.
11. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci U S A 1999, 96:8150-8155. 10.1073/pnas.96.14.8150, 22203, 10393963.
12. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004, 382:115-144.
13. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995, 72:555-561. 10.1038/bjc.1995.373, 2033894, 7669561.
14. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P. Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 2004, 12:848-854. 10.1038/sj.ejhg.5201249, 15280903.
15. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 2004, 90:1989-1994. 10.1038/sj.bjc.6601779, 2410282, 15138483.
16. Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP. Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 2011, 15:343-349. 10.1089/gtmb.2010.0197, 21329464.
17. Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, Li D. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 2011, 125:467-472. 10.1007/s10549-010-0966-0, 20526805.
18. Yao S, Xu H, Chen Y, Shen X, Ju X, Wu W, Huang H, Dai L. Relationship between genetic polymorphisms of quinone oxidoreductase 1 and susceptibility and chemosensitivity of breast cancer. Chin J Exp Surg 2013, 125:684-687.
19. Lajin B, Alhaj Sakur A, Alachkar A. Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Res Treat 2013, 138:611-619. 10.1007/s10549-013-2467-4, 23468244.
20. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF, Helms PJ, Hakonarson H, Halpi E, Navon R, Attia J. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005, 162:201-211. 10.1093/aje/kwi184, 15987731.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
23. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004, 13:1308-1315.
24. Siegelmann-Danieli N, Buetow KH. Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 2002, 62:39-45. 10.1159/000048245, 11810042.
25. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y, Ogura M, Ando M, Sugimura Y, Tajima K. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002, 7:103-108.
26. Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA, Mitchell DS, Shimasaki CD, Mulvihill JJ, Jupe ER. Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet 2005, 116:208-221. 10.1007/s00439-004-1206-7, 15611867.
27. Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X, Li S. Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol 2014, 9:74. 10.1186/1746-1596-9-74, 3977697, 24666463.
28. Wang Z, Zhang Y, Kong X, Li S, Hu Y, Wang R, Li Y, Lu C, Lin N, Chen W. Association of a polymorphism in PON-1 gene with steroid-induced osteonecrosis of femoral head in Chinese Han population. Diagn Pathol 2013, 8:186. 10.1186/1746-1596-8-186, 24206655.
29. Dou K, Xu Q, Han X. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol 2013, 8:112. 10.1186/1746-1596-8-112, 3744163, 23819639.
30. Siegel D, Yan C, Ross D. NAD(P)H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012, 83:1033-1040. 10.1016/j.bcp.2011.12.017, 3482497, 22209713.
31. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010, 501:116-123. 10.1016/j.abb.2010.03.019, 2930038, 20361926.
32. Yu L, Chen J. Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an update meta-analysis based on 51 research studies. Diagn Pathol 2012, 7:171. 10.1186/1746-1596-7-171, 3536596, 23217001.
33. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol 2008, 168:1221-1232. 2727266, 18945694.
34. Zhang Y, Liu L, Tang Y, Chen C, Wang Q, Xu J, Yang C, Miao X, Wei S, Chen J, Nie S. Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study. Mol Biol Rep 2012, 39:9661-9668. 10.1007/s11033-012-1831-5, 22744426.
35. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:979-987. 10.1158/1055-9965.EPI-05-0899, 16702380.
36. Lou Y, Li R, Xiong L, Gu A, Shi C, Chu T, Zhang X, Gu P, Zhong H, Wen S, Han B. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour Biol 2013, 34:3967-3979. 10.1007/s13277-013-0985-7, 23852860.
37. Liu K, Tian H, Yu KZ, Shen WY, Mao ZC, Jin CH, Pan HB, He JX. Association between NQO1 Pro187Ser polymorphism and esophageal cancer: a meta-analysis. Tumour Biol 2013, 35:2063-2068.
38. Liu F, Luo L, Wei Y, Wang W, Li B, Yan L, Wen T. A functional NQO1 609C > T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 2013, 34:47-53. 10.1007/s13277-012-0509-x, 22972504.
39. Danson S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 2004, 30:437-449. 10.1016/j.ctrv.2004.01.002, 15245776.
40. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914-916. 10.1136/bmj.39343.408449.80, 2048840, 17974687.
41. Xu Z, Yu L, Zhang X. Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects. Diagn Pathol 2013, 8:144. 10.1186/1746-1596-8-144, 3853705, 23971971.